RD Saúde (RADL3)

Greenhouse gas emissions & sustainability report data

📊 Latest report period: 2023🗂️ Report periods on file: 2023

In its 2023 reporting, RD Saúde (RADL3) disclosed greenhouse gas emissions of 586.8K tCO2e (2023). By scope: Scope 1: 21.0K tCO2e (2023); Scope 2: 3.8K tCO2e (2023 market-based); Scope 3: 562.0K tCO2e (2023). Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.

💨
GHG Emissions
586.8K tCO2e (2023)
2023
⚡
Renewable Energy
72%
of total energy
💧
Water Usage
670.59 megaliters (2023)
2023
♻️
Waste
26.2K tons (2023)
2023
⚙️
Energy Use
972.4K GJ (2023)
2023

📊 Emissions by Scope (2023)

ScopeWhat it coversReported value
Scope 1Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions).21.0K tCO2e (2023)
Scope 2Indirect emissions from purchased electricity, steam, heat and cooling.3.8K tCO2e (2023 market-based)
Scope 3Other indirect emissions across the value chain (purchased goods, business travel, use of sold products, etc.).562.0K tCO2e (2023)

New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.

✅ Reported Environmental Achievements

🎯 Climate & Sustainability Targets

📅 Medium-term

  • 100% renewable energy by 2030
  • 3,000 tons of collected pharmaceutical waste by 2030

🌱 ESG Focus Areas

EnvironmentalSocialGovernance

⚠️ Challenges & Risks +

  • Climate-related risks (physical and transition)
  • Water consumption in areas with water stress
  • Employee turnover, mainly in the pharmacy service area
  • Greenhouse gas and other pollutant emissions
  • Social impacts on the supply chain
  • Technology system failures and disruptions

📋 Report Information

Reporting Period: 2023
Frameworks: GRI Standards (2021)
Assurance: KPMG